Lipa Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
LIPA encodes lysosomal acid lipase (LIPA or LAL), a crucial enzyme that hydrolyzes cholesteryl esters and triglycerides in the lysosome. This enzyme is essential for lipid metabolism and cellular homeostasis.
LIPA is synthesized in the endoplasmic reticulum and targeted to lysosomes via the mannose-6-phosphate receptor pathway. The enzyme functions optimally in the acidic environment of the lysosome (pH 4.5-5.0).
Key functions include:
Severe LIPA deficiency causes Wolman disease, a fatal lysosomal storage disorder:
Partial LIPA deficiency causes CESD:
LIPA dysfunction may contribute to neurodegenerative diseases:
LIPA is expressed in:
In the brain, LIPA expression is detected in neurons, astrocytes, and microglia, with particular importance in lipid-rich regions like white matter.
Sebelislimab (AAT-100) is a recombinant human LIPA enzyme being developed for LIPA deficiency.
AAV-vector based gene therapy approaches are being explored for LIPA.
Understanding LIPA function may provide insights into:
The study of Lipa Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.